Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer.
Fiche publication
Date publication
mai 2023
Journal
EBioMedicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr FUMET Jean-David, Pr BIBEAU Frédéric
Tous les auteurs :
Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, Laugé C, Catteau A, Boquet I, Majdi A, Morgand E, Oulkhouir Y, Brandone N, Adam J, Sbarrato T, Kassambara A, Fieschi J, Garcia S, Lepage AL, Tomasini P, Galon J
Lien Pubmed
Résumé
Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response are currently lacking.
Mots clés
Digital pathology, Immunoscore-IC, Immunotherapy, Non-small cell lung cancer, Prognostic marker
Référence
EBioMedicine. 2023 05 25;92:104633